Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02438306 · ClinicalTrials.gov registry record · Phase 3
CardiAMP™ Cell Therapy for Heart Failure Trial
A Phase 3 study, sponsored by BioCardia.
- Completed
- Registry status
- Phase 3
- Development phase
- 125
- Enrollment target
NCT02438306 is a Phase 3 study that has completed, run by BioCardia. The registered enrollment target is 125 participants.
The verdict
NCT02438306, a Phase 3 study, has completed, sponsored by BioCardia.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 125 participants
- Enrollment target
Study Summary
This is a prospective, multi-center, randomized, controlled, patient- and evaluator-blinded study comparing treatment with the CardiAMP cell therapy to a sham control treatment. A roll-in phase with a maximum of 10 subjects may occur.
Interventions
- OTHER Sham
- BIOLOGICAL Autologous cell therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2016-12 |
| Est. Completion | 2025-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02438306
The ClinicalTrials.gov registry entry for NCT02438306 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioCardia, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.
NCT02438306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02438306 about?
NCT02438306 is a clinical study titled "CardiAMP™ Cell Therapy for Heart Failure Trial". This is a prospective, multi-center, randomized, controlled, patient- and evaluator-blinded study comparing treatment with the CardiAMP cell therapy to a sham control treatment. A roll-in phase with a maximum of 10 subjects may occur.
What is the current status of trial NCT02438306?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2016-12. Estimated completion is 2025-06.
What interventions are being tested in trial NCT02438306?
The interventions under investigation include: Sham (OTHER), Autologous cell therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT02438306?
This trial is sponsored by BioCardia, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.